The global Platinum-based Antineoplastic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Platinum-based Antineoplastic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Platinum-based Antineoplastic.

Report Scope

The Platinum-based Antineoplastic market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Platinum-based Antineoplastic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Platinum-based Antineoplastic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Platinum-based Antineoplastic Market Report

Report Metric	Details
Report Name	Platinum-based Antineoplastic Market
CAGR	5%
Segment by Type	Cisplatin Carboplatin Nedaplatin Oxaliplatin Lobaplatin Cycloplatin
Segment by Application	Combination Therapy Monotherapy Targeted Therapy
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie, Novartis, GSK, MSD, Hengrui Medicine, Hansoh Pharmaceutical Group, ChiTaiTianQing Pharmaceutical Group, CSPC Pharmaceutical Group
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Platinum-based Antineoplastic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Platinum-based Antineoplastic Market report?

Ans: The main players in the Platinum-based Antineoplastic Market are Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie, Novartis, GSK, MSD, Hengrui Medicine, Hansoh Pharmaceutical Group, ChiTaiTianQing Pharmaceutical Group, CSPC Pharmaceutical Group

What are the Application segmentation covered in the Platinum-based Antineoplastic Market report?

Ans: The Applications covered in the Platinum-based Antineoplastic Market report are Combination Therapy, Monotherapy, Targeted Therapy

What are the Type segmentation covered in the Platinum-based Antineoplastic Market report?

Ans: The Types covered in the Platinum-based Antineoplastic Market report are Cisplatin, Carboplatin, Nedaplatin, Oxaliplatin, Lobaplatin, Cycloplatin

1 Platinum-based Antineoplastic Market Overview

1.1 Product Overview and Scope of Platinum-based Antineoplastic

1.2 Platinum-based Antineoplastic Segment by Type

1.2.1 Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2030)

1.2.2 Cisplatin

1.2.3 Carboplatin

1.2.4 Nedaplatin

1.2.5 Oxaliplatin

1.2.6 Lobaplatin

1.2.7 Cycloplatin

1.3 Platinum-based Antineoplastic Segment by Application

1.3.1 Global Platinum-based Antineoplastic Market Value by Application: (2024-2030)

1.3.2 Combination Therapy

1.3.3 Monotherapy

1.3.4 Targeted Therapy

1.4 Global Platinum-based Antineoplastic Market Size Estimates and Forecasts

1.4.1 Global Platinum-based Antineoplastic Revenue 2019-2030

1.4.2 Global Platinum-based Antineoplastic Sales 2019-2030

1.4.3 Global Platinum-based Antineoplastic Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Platinum-based Antineoplastic Market Competition by Manufacturers

2.1 Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2019-2024)

2.2 Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Platinum-based Antineoplastic Average Price by Manufacturers (2019-2024)

2.4 Global Platinum-based Antineoplastic Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application

2.7 Platinum-based Antineoplastic Market Competitive Situation and Trends

2.7.1 Platinum-based Antineoplastic Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Platinum-based Antineoplastic Players Market Share by Revenue

2.7.3 Global Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Platinum-based Antineoplastic Retrospective Market Scenario by Region

3.1 Global Platinum-based Antineoplastic Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Platinum-based Antineoplastic Global Platinum-based Antineoplastic Sales by Region: 2019-2030

3.2.1 Global Platinum-based Antineoplastic Sales by Region: 2019-2024

3.2.2 Global Platinum-based Antineoplastic Sales by Region: 2025-2030

3.3 Global Platinum-based Antineoplastic Global Platinum-based Antineoplastic Revenue by Region: 2019-2030

3.3.1 Global Platinum-based Antineoplastic Revenue by Region: 2019-2024

3.3.2 Global Platinum-based Antineoplastic Revenue by Region: 2025-2030

3.4 North America Platinum-based Antineoplastic Market Facts & Figures by Country

3.4.1 North America Platinum-based Antineoplastic Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Platinum-based Antineoplastic Sales by Country (2019-2030)

3.4.3 North America Platinum-based Antineoplastic Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Platinum-based Antineoplastic Market Facts & Figures by Country

3.5.1 Europe Platinum-based Antineoplastic Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Platinum-based Antineoplastic Sales by Country (2019-2030)

3.5.3 Europe Platinum-based Antineoplastic Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Platinum-based Antineoplastic Market Facts & Figures by Country

3.6.1 Asia Pacific Platinum-based Antineoplastic Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Platinum-based Antineoplastic Sales by Country (2019-2030)

3.6.3 Asia Pacific Platinum-based Antineoplastic Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Platinum-based Antineoplastic Market Facts & Figures by Country

3.7.1 Latin America Platinum-based Antineoplastic Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Platinum-based Antineoplastic Sales by Country (2019-2030)

3.7.3 Latin America Platinum-based Antineoplastic Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Platinum-based Antineoplastic Market Facts & Figures by Country

3.8.1 Middle East and Africa Platinum-based Antineoplastic Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Platinum-based Antineoplastic Sales by Country (2019-2030)

3.8.3 Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Platinum-based Antineoplastic Sales by Type (2019-2030)

4.1.1 Global Platinum-based Antineoplastic Sales by Type (2019-2024)

4.1.2 Global Platinum-based Antineoplastic Sales by Type (2025-2030)

4.1.3 Global Platinum-based Antineoplastic Sales Market Share by Type (2019-2030)

4.2 Global Platinum-based Antineoplastic Revenue by Type (2019-2030)

4.2.1 Global Platinum-based Antineoplastic Revenue by Type (2019-2024)

4.2.2 Global Platinum-based Antineoplastic Revenue by Type (2025-2030)

4.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Type (2019-2030)

4.3 Global Platinum-based Antineoplastic Price by Type (2019-2030)

5 Segment by Application

5.1 Global Platinum-based Antineoplastic Sales by Application (2019-2030)

5.1.1 Global Platinum-based Antineoplastic Sales by Application (2019-2024)

5.1.2 Global Platinum-based Antineoplastic Sales by Application (2025-2030)

5.1.3 Global Platinum-based Antineoplastic Sales Market Share by Application (2019-2030)

5.2 Global Platinum-based Antineoplastic Revenue by Application (2019-2030)

5.2.1 Global Platinum-based Antineoplastic Revenue by Application (2019-2024)

5.2.2 Global Platinum-based Antineoplastic Revenue by Application (2025-2030)

5.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Application (2019-2030)

5.3 Global Platinum-based Antineoplastic Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Corporation Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Pfizer Platinum-based Antineoplastic Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Roche

6.3.1 Roche Corporation Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Roche Platinum-based Antineoplastic Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Corporation Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Bristol-Myers Squibb

6.5.1 Bristol-Myers Squibb Corporation Information

6.5.2 Bristol-Myers Squibb Description and Business Overview

6.5.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio

6.5.5 Bristol-Myers Squibb Recent Developments/Updates

6.6 Asta Medica GmbH

6.6.1 Asta Medica GmbH Corporation Information

6.6.2 Asta Medica GmbH Description and Business Overview

6.6.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio

6.6.5 Asta Medica GmbH Recent Developments/Updates

6.7 Simcere Pharmaceutical

6.6.1 Simcere Pharmaceutical Corporation Information

6.6.2 Simcere Pharmaceutical Description and Business Overview

6.6.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio

6.7.5 Simcere Pharmaceutical Recent Developments/Updates

6.8 Abbvie

6.8.1 Abbvie Corporation Information

6.8.2 Abbvie Description and Business Overview

6.8.3 Abbvie Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Abbvie Platinum-based Antineoplastic Product Portfolio

6.8.5 Abbvie Recent Developments/Updates

6.9 Novartis

6.9.1 Novartis Corporation Information

6.9.2 Novartis Description and Business Overview

6.9.3 Novartis Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Novartis Platinum-based Antineoplastic Product Portfolio

6.9.5 Novartis Recent Developments/Updates

6.10 GSK

6.10.1 GSK Corporation Information

6.10.2 GSK Description and Business Overview

6.10.3 GSK Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.10.4 GSK Platinum-based Antineoplastic Product Portfolio

6.10.5 GSK Recent Developments/Updates

6.11 MSD

6.11.1 MSD Corporation Information

6.11.2 MSD Platinum-based Antineoplastic Description and Business Overview

6.11.3 MSD Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.11.4 MSD Platinum-based Antineoplastic Product Portfolio

6.11.5 MSD Recent Developments/Updates

6.12 Hengrui Medicine

6.12.1 Hengrui Medicine Corporation Information

6.12.2 Hengrui Medicine Platinum-based Antineoplastic Description and Business Overview

6.12.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio

6.12.5 Hengrui Medicine Recent Developments/Updates

6.13 Hansoh Pharmaceutical Group

6.13.1 Hansoh Pharmaceutical Group Corporation Information

6.13.2 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview

6.13.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio

6.13.5 Hansoh Pharmaceutical Group Recent Developments/Updates

6.14 ChiTaiTianQing Pharmaceutical Group

6.14.1 ChiTaiTianQing Pharmaceutical Group Corporation Information

6.14.2 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview

6.14.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.14.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio

6.14.5 ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates

6.15 CSPC Pharmaceutical Group

6.15.1 CSPC Pharmaceutical Group Corporation Information

6.15.2 CSPC Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview

6.15.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2019-2024)

6.15.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio

6.15.5 CSPC Pharmaceutical Group Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Platinum-based Antineoplastic Industry Chain Analysis

7.2 Platinum-based Antineoplastic Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Platinum-based Antineoplastic Production Mode & Process

7.4 Platinum-based Antineoplastic Sales and Marketing

7.4.1 Platinum-based Antineoplastic Sales Channels

7.4.2 Platinum-based Antineoplastic Distributors

7.5 Platinum-based Antineoplastic Customers

8 Platinum-based Antineoplastic Market Dynamics

8.1 Platinum-based Antineoplastic Industry Trends

8.2 Platinum-based Antineoplastic Market Drivers

8.3 Platinum-based Antineoplastic Market Challenges

8.4 Platinum-based Antineoplastic Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Simcere Pharmaceutical

CSPC Pharmaceutical Group

Asta Medica GmbH

Hansoh Pharmaceutical Group

ChiTaiTianQing Pharmaceutical Group

List of Tables

Table 1. Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Platinum-based Antineoplastic Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Platinum-based Antineoplastic Market Competitive Situation by Manufacturers in 2023

Table 4. Global Platinum-based Antineoplastic Sales (Units) of Key Manufacturers (2019-2024)

Table 5. Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Platinum-based Antineoplastic Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Platinum-based Antineoplastic Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Platinum-based Antineoplastic Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Platinum-based Antineoplastic, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application

Table 12. Global Key Manufacturers of Platinum-based Antineoplastic, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Platinum-based Antineoplastic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum-based Antineoplastic as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Platinum-based Antineoplastic Sales by Region (2019-2024) & (Units)

Table 18. Global Platinum-based Antineoplastic Sales Market Share by Region (2019-2024)

Table 19. Global Platinum-based Antineoplastic Sales by Region (2025-2030) & (Units)

Table 20. Global Platinum-based Antineoplastic Sales Market Share by Region (2025-2030)

Table 21. Global Platinum-based Antineoplastic Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Platinum-based Antineoplastic Revenue Market Share by Region (2019-2024)

Table 23. Global Platinum-based Antineoplastic Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Platinum-based Antineoplastic Revenue Market Share by Region (2025-2030)

Table 25. North America Platinum-based Antineoplastic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Platinum-based Antineoplastic Sales by Country (2019-2024) & (Units)

Table 27. North America Platinum-based Antineoplastic Sales by Country (2025-2030) & (Units)

Table 28. North America Platinum-based Antineoplastic Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Platinum-based Antineoplastic Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Platinum-based Antineoplastic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Platinum-based Antineoplastic Sales by Country (2019-2024) & (Units)

Table 32. Europe Platinum-based Antineoplastic Sales by Country (2025-2030) & (Units)

Table 33. Europe Platinum-based Antineoplastic Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Platinum-based Antineoplastic Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Platinum-based Antineoplastic Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Platinum-based Antineoplastic Sales by Region (2019-2024) & (Units)

Table 37. Asia Pacific Platinum-based Antineoplastic Sales by Region (2025-2030) & (Units)

Table 38. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Platinum-based Antineoplastic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Platinum-based Antineoplastic Sales by Country (2019-2024) & (Units)

Table 42. Latin America Platinum-based Antineoplastic Sales by Country (2025-2030) & (Units)

Table 43. Latin America Platinum-based Antineoplastic Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Platinum-based Antineoplastic Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Platinum-based Antineoplastic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2019-2024) & (Units)

Table 47. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2025-2030) & (Units)

Table 48. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Platinum-based Antineoplastic Sales (Units) by Type (2019-2024)

Table 51. Global Platinum-based Antineoplastic Sales (Units) by Type (2025-2030)

Table 52. Global Platinum-based Antineoplastic Sales Market Share by Type (2019-2024)

Table 53. Global Platinum-based Antineoplastic Sales Market Share by Type (2025-2030)

Table 54. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Platinum-based Antineoplastic Revenue Market Share by Type (2019-2024)

Table 57. Global Platinum-based Antineoplastic Revenue Market Share by Type (2025-2030)

Table 58. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2019-2024)

Table 59. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2025-2030)

Table 60. Global Platinum-based Antineoplastic Sales (Units) by Application (2019-2024)

Table 61. Global Platinum-based Antineoplastic Sales (Units) by Application (2025-2030)

Table 62. Global Platinum-based Antineoplastic Sales Market Share by Application (2019-2024)

Table 63. Global Platinum-based Antineoplastic Sales Market Share by Application (2025-2030)

Table 64. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Platinum-based Antineoplastic Revenue Market Share by Application (2019-2024)

Table 67. Global Platinum-based Antineoplastic Revenue Market Share by Application (2025-2030)

Table 68. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2019-2024)

Table 69. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2025-2030)

Table 70. Pfizer Corporation Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Pfizer Platinum-based Antineoplastic Product

Table 74. Pfizer Recent Developments/Updates

Table 75. AstraZeneca Corporation Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. AstraZeneca Platinum-based Antineoplastic Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Roche Corporation Information

Table 81. Roche Description and Business Overview

Table 82. Roche Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Roche Platinum-based Antineoplastic Product

Table 84. Roche Recent Developments/Updates

Table 85. Sanofi Corporation Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Sanofi Platinum-based Antineoplastic Product

Table 89. Sanofi Recent Developments/Updates

Table 90. Bristol-Myers Squibb Corporation Information

Table 91. Bristol-Myers Squibb Description and Business Overview

Table 92. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Bristol-Myers Squibb Platinum-based Antineoplastic Product

Table 94. Bristol-Myers Squibb Recent Developments/Updates

Table 95. Asta Medica GmbH Corporation Information

Table 96. Asta Medica GmbH Description and Business Overview

Table 97. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Asta Medica GmbH Platinum-based Antineoplastic Product

Table 99. Asta Medica GmbH Recent Developments/Updates

Table 100. Simcere Pharmaceutical Corporation Information

Table 101. Simcere Pharmaceutical Description and Business Overview

Table 102. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Simcere Pharmaceutical Platinum-based Antineoplastic Product

Table 104. Simcere Pharmaceutical Recent Developments/Updates

Table 105. Abbvie Corporation Information

Table 106. Abbvie Description and Business Overview

Table 107. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Abbvie Platinum-based Antineoplastic Product

Table 109. Abbvie Recent Developments/Updates

Table 110. Novartis Corporation Information

Table 111. Novartis Description and Business Overview

Table 112. Novartis Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Novartis Platinum-based Antineoplastic Product

Table 114. Novartis Recent Developments/Updates

Table 115. GSK Corporation Information

Table 116. GSK Description and Business Overview

Table 117. GSK Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. GSK Platinum-based Antineoplastic Product

Table 119. GSK Recent Developments/Updates

Table 120. MSD Corporation Information

Table 121. MSD Description and Business Overview

Table 122. MSD Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. MSD Platinum-based Antineoplastic Product

Table 124. MSD Recent Developments/Updates

Table 125. Hengrui Medicine Corporation Information

Table 126. Hengrui Medicine Description and Business Overview

Table 127. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Hengrui Medicine Platinum-based Antineoplastic Product

Table 129. Hengrui Medicine Recent Developments/Updates

Table 130. Hansoh Pharmaceutical Group Corporation Information

Table 131. Hansoh Pharmaceutical Group Description and Business Overview

Table 132. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product

Table 134. Hansoh Pharmaceutical Group Recent Developments/Updates

Table 135. ChiTaiTianQing Pharmaceutical Group Corporation Information

Table 136. ChiTaiTianQing Pharmaceutical Group Description and Business Overview

Table 137. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product

Table 139. ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates

Table 140. CSPC Pharmaceutical Group Corporation Information

Table 141. CSPC Pharmaceutical Group Description and Business Overview

Table 142. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product

Table 144. CSPC Pharmaceutical Group Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Platinum-based Antineoplastic Distributors List

Table 148. Platinum-based Antineoplastic Customers List

Table 149. Platinum-based Antineoplastic Market Trends

Table 150. Platinum-based Antineoplastic Market Drivers

Table 151. Platinum-based Antineoplastic Market Challenges

Table 152. Platinum-based Antineoplastic Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Platinum-based Antineoplastic

Figure 2. Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Platinum-based Antineoplastic Market Share by Type in 2023 & 2030

Figure 4. Cisplatin Product Picture

Figure 5. Carboplatin Product Picture

Figure 6. Nedaplatin Product Picture

Figure 7. Oxaliplatin Product Picture

Figure 8. Lobaplatin Product Picture

Figure 9. Cycloplatin Product Picture

Figure 10. Global Platinum-based Antineoplastic Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 11. Global Platinum-based Antineoplastic Market Share by Application in 2023 & 2030

Figure 12. Combination Therapy

Figure 13. Monotherapy

Figure 14. Targeted Therapy

Figure 15. Global Platinum-based Antineoplastic Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Platinum-based Antineoplastic Market Size (2019-2030) & (US$ Million)

Figure 17. Global Platinum-based Antineoplastic Sales (2019-2030) & (Units)

Figure 18. Global Platinum-based Antineoplastic Average Price (US$/Unit) & (2019-2030)

Figure 19. Platinum-based Antineoplastic Report Years Considered

Figure 20. Platinum-based Antineoplastic Sales Share by Manufacturers in 2023

Figure 21. Global Platinum-based Antineoplastic Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest Platinum-based Antineoplastic Players: Market Share by Revenue in 2023

Figure 23. Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America Platinum-based Antineoplastic Sales Market Share by Country (2019-2030)

Figure 26. North America Platinum-based Antineoplastic Revenue Market Share by Country (2019-2030)

Figure 27. United States Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe Platinum-based Antineoplastic Sales Market Share by Country (2019-2030)

Figure 30. Europe Platinum-based Antineoplastic Revenue Market Share by Country (2019-2030)

Figure 31. Germany Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Platinum-based Antineoplastic Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific Platinum-based Antineoplastic Revenue Market Share by Region (2019-2030)

Figure 38. China Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. China Taiwan Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Platinum-based Antineoplastic Sales Market Share by Country (2019-2030)

Figure 46. Latin America Platinum-based Antineoplastic Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. UAE Platinum-based Antineoplastic Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Platinum-based Antineoplastic by Type (2019-2030)

Figure 56. Global Revenue Market Share of Platinum-based Antineoplastic by Type (2019-2030)

Figure 57. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2019-2030)

Figure 58. Global Sales Market Share of Platinum-based Antineoplastic by Application (2019-2030)

Figure 59. Global Revenue Market Share of Platinum-based Antineoplastic by Application (2019-2030)

Figure 60. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2019-2030)

Figure 61. Platinum-based Antineoplastic Value Chain

Figure 62. Platinum-based Antineoplastic Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Oncology Imaging Equipment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-1U15802

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global HER2 Tumor Marker Testing Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-27D15553

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Targeted Radiotherapy Drug Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2U15903

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2W15676

Tue Aug 27 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions